临床试验/NCT00873210

NCT00873210已完成不适用

Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent

Pfizer1 个研究点分布在 1 个国家目标入组 121 人开始时间: 2009年5月最近更新: 2012年11月9日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Pfizer
入组人数: 121
试验地点: 1
主要终点: Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

详细描述

Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

排除标准

•Hypersensitivity to sunitinib malate or to any of the excipients
•Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).

研究组 & 干预措施

Patients treated with Sutent

125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

干预措施: Sutent (Drug)

结局指标

主要结局

Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib

时间窗: 36 months

次要结局

Dose modifications(36 months)
Incidence of new diagnosed hypertension(36 months)
Incidence of new diagnosed hypothyroidism(36 months)
Safety of sunitinib malate in "real-life" setting(36 months)
Efficacy of sunitinib malate in "real-life" setting(36 months)

研究者

发起方

Pfizer

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®Metastatic Renal Cell Carcinoma

NCT00684645Pfizer186

已完成

不适用

Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor TherapyBreast Neoplasms

NCT00784888Pfizer344

已完成

不适用

Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular DegenerationNeovascular Macular DegenerationMacular DegenerationAge-related Macular Degeneration

NCT01245387Pfizer1,001

已完成

不适用

Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)Common Cold

NCT00480194Nycomed1,000

已完成

不适用

NCT03134911Boehringer Ingelheim535